Goldman Sachs Initiates Avis Budget Group at Sell
(Updated - December 7, 2023 4:07 AM EST) Goldman Sachs initiates coverage on Avis Budget Group (NASDAQ:CAR) at Sell, PT $164.00.Analysts comment "While CAR has been executing better than...
Buy
or
Avis News & Analysis
-
-
Avis Budget Group Declares $10.00 Special Dividend; 5.4% Yield
Avis Budget Group (NASDAQ:CAR) declared a special dividend of $10.00 per share. The dividend will be payable on December 21, 2023, to stockholders of record on December 15, 2023, with an...
-
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Tuesday, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA-...
-
Air India Flouts CAR Norms, Aviation Watchdog ‘DGCA’ Slaps Rs 10 Lakh Fine
DGCA inspections revealed Air India's non-compliance with aviation regulations at Kochi, Bengaluru, and Delhi airports, leading to a Rs 10 lakh penalty.
-
Avis Budget Group Prices $500M Notes Offering
Avis Budget Group, Inc. (CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc. (together, the “Issuers”) priced a...
-
Avis Budget Group to Offer $500M of Senior Notes
Avis Budget Group, Inc. (CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc. (together, the “Issuers”), intend,...
-
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
Phase 1 trial to investigate multiple B-cell mediated autoimmune diseases First healthy donor-derived allogeneic CAR T cell therapy to announce IND clearance Expect to disclose initial...
-
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Addition of Affimed's innate cell engager (ICE®) improves cytotoxicity of natural killer (NK) cells and CAR-NK cells NK cells with ICE® show at least comparable anti-tumor cell efficacy to...
-
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and...
-
JPMorgan maintains Avis at 'overweight' with a price target of $280.00
An analyst from JPMorgan maintained Avis (NASDAQ: CAR) at 'overweight' with a price target of $280.00 from a prior price target of %currency%%price%. Prior to this rating, Avis had 3 buy...
-
Earnings call: Avis Budget Group's Q3 2023 Performance Reveals Record Revenue, Focus on EVs, and Strategic Pricing
Avis Budget (NASDAQ:CAR) Group reported record quarterly revenue of $3.6 billion and adjusted EBITDA of over $900 million in Q3 2023, according to the recent earnings call. The company...
-
Avis Budget Group shares rally as peak demand drives performance
Avis Budget Group (NASDAQ:CAR) is up over 5% ahead of Thursday's open after reporting earnings for its latest quarter, which topped consensus expectations. The car rental company...
-
Avis Budget Group Appoints Izzy Martins as CFO
On November 1, 2023, Avis Budget Group (CAR) announced that Izzy Martins, currently serving as EVP Americas of the Company, will assume the role of EVP & Chief Financial Officer of the...
-
Avis earnings beat by $2.54, revenue topped estimates
Investing.com - Avis (NASDAQ: CAR) reported third quarter EPS of $16.78, $2.54 better than the analyst estimate of $14.24. Revenue for the quarter came in at $3.6B versus the consensus...
-
King Faisal Specialist Hospital and Research Centre Celebrates the Success of Treating 100 Patients with Lymphocytic Leukemia Using CAR T-Cells
RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- In a new step that offers cancer patients a glimmer of hope and a lifeline, the King Faisal Specialist Hospital and Research Centre...
-
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical...
-
Jefferies maintains Avis at 'buy' with a price target of $280.00
An analyst from Jefferies maintained Avis (NASDAQ: CAR) at 'buy' with a price target of $280.00 from a prior price target of %currency%%price%. Prior to this rating, Avis had 3 buy...
-
Deutsche Bank Opens Catalyst Call Buy Idea on Avis Budget Group
Deutsche Bank (ETR:DBKGn) analysts reiterated a Hold rating and $260.00 price target on Avis Budget Group (CAR).The analysts comment "We see CAR shares as being inexpensive at current...
-
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug...
-
IIT-B startup ImmunoACT's “affordable” blood cancer therapy gets regulatory approval - a first for India's CAR-T cell therapy
The Indian drug regulator has granted approval to ImmunoACT for its CAR-T cell therapy NexCAR19, designed to treat certain types of blood cancers. The therapy will be used for the treatment...
-
Avis Budget Group Issues $300M of Asset-Backed Securities
On September 18, 2023 (the “Closing Date”), our Avis Budget Group (CAR) Funding (AESOP) LLC subsidiary (“ABRCF”) issued $300 million of asset-backed securities with a maturity of three...
-
Jefferies maintains Avis at 'buy' with a price target of $319.00
An analyst from Jefferies maintained Avis (NASDAQ: CAR) at 'buy' with a price target of $319.00 from a prior price target of %currency%%price%. Prior to this rating, Avis had 3 buy...
-
JPMorgan maintains Avis at 'overweight' with a price target of $275.00
An analyst from JPMorgan maintained Avis (NASDAQ: CAR) at 'overweight' with a price target of $275.00 from a prior price target of %currency%%price%. Prior to this rating, Avis had 3 buy...
-
After-hours movers: ZoomInfo sinks on weak guidance, Arista Networks gains on results
After-Hours Stock Movers: ZoomInfo Technologies Inc (NASDAQ:ZI) 17% LOWER; reported Q2 EPS of $0.26, $0.03 better than the analyst estimate of $0.23. {{erl-1161497||Revenue for the quarter...
-
Avis Q2 earnings top estimates, driven by 'robust' summer demand
Invesitng.com -- Avis reported Monday second-quarter earnings that markedly beat Wall Street estimate as "robust" summer travel bolstered demand. Avis Budget Group Inc (NASDAQ:CAR) was...
-
Avis earnings beat by $1.57, revenue fell short of estimates
Investing.com - Avis (NASDAQ: CAR) reported second quarter EPS of $11.01, $1.57 better than the analyst estimate of $9.44. Revenue for the quarter came in at $3.12B versus the consensus...
-
Avis Budget Group potenial upside 'somewhat limited from here' - Deutsche Bank
Avis Budget Group (NASDAQ:CAR) was cut to Hold from Buy at Deutsche Bank on Thursday, with analysts maintaining a $263 price target on the stock. The analysts told investors in a...
-
Deutsche Bank downgrades Avis to 'hold' with a price target of $263.00
An analyst from Deutsche Bank downgraded Avis (NASDAQ: CAR) from 'buy' to 'hold' with a price target of $263.00. Prior to this rating, Avis had 4 buy ratings, 2 hold ratings, and 0 sell...
-
Avis Budget Group Announces EUR 400M Senior Notes Offering
Avis Budget Group, Inc. (NASDAQ:CAR) (the “Company”) announced today that its wholly-owned subsidiary, Avis Budget Finance plc (the “Issuer”), intends, subject to market and other...
-
4 big analyst picks: Spotify gains on upgrade, Ball raised to Equal-weight
Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades at |Spotify, Ball, Avis Budget Group, and Melco Resorts & Entertainment.InvestingPro...
-
Avis Budget Group lifted as Morgan Stanley sees 'higher floor for the industry'
Morgan Stanley analysts upgraded Avis Budget Group (NASDAQ:CAR) to Overweight from Equal-Weight, raising the firm's price target on the stock to $230 from $182 in a note to clients...
-
FedEx, Avis and PayPal rise premarket; Palantir falls
Investing.com -- Stocks in focus in premarket trade on Tuesday, June 20th. Please refresh for updates. FedEx (NYSE:FDX) stock rose 0.5% ahead of the delivery giant’s quarterly...
-
Morgan Stanley upgrades Avis to 'overweight' with a price target of $230.00
An analyst from Morgan Stanley upgraded Avis (NASDAQ: CAR) from 'equalweight' to 'overweight' with a price target of $230.00 from a prior price target of %currency%%price%. Prior to this...
-
4 big analyst picks: Avis Budget zooms higher on Deutsche upgrade
By Davit KirakosyanHere is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades at |Avis Budget, Q2, bluebird bio, Equitrans Midstream, and Financial...
-
HP, Hewlett Packard Enterprise and Goldman Sachs fall premarket; Avis rises
Investing.com -- Stocks in focus in premarket trade on Wednesday, May 31st. Please refresh for updates. HP (NYSE:HPQ) stock fell 6.2% after the PC maker {{erl-8270||posted its lowest...
-
Deutsche Bank says Avis Budget Group 'left behind without cause,' too much negativity in shares
Avis Budget Group (NASDAQ:CAR) was lifted to Buy from Hold at Deutsche Bank on Wednesday, with analysts raising the firm's price target on the stock to $263 from $239 per share. CAR...
-
Deutsche Bank upgrades Avis to 'buy' with a price target of $263.00
An analyst from Deutsche Bank upgraded Avis (NASDAQ: CAR) from 'hold' to 'buy' with a price target of $263.00 from a prior price target of %currency%%price%. Prior to this rating, Avis had...
-
Morgan Stanley upgrades Avis to Equalweight, PT $182.00
A Morgan Stanley analyst upgraded Avis (NASDAQ: CAR) from Underweight to Equalweight with a price target of $182.00 from a prior price target of %currency%%price%. Prior to this rating, Avis...
-
Susquehanna maintains Avis at Neutral, PT $195.00
A Susquehanna analyst maintained Avis (NASDAQ: CAR) at Neutral and a price target of $195.00 from a prior price target of %currency%%price%. Prior to this rating, Avis had 2 buy ratings, 3...
-
Avis earnings beat by $4.77, revenue topped estimates
Investing.com - Avis (NASDAQ: CAR) reported first quarter EPS of $7.72, $4.77 better than the analyst estimate of $2.95. Revenue for the quarter came in at $2.6B versus the consensus...
-
JPMorgan maintains Avis at Overweight, PT $280.00
A JPMorgan analyst maintained Avis (NASDAQ: CAR) at Overweight and a price target of $280.00 from a prior price target of %currency%%price%. Prior to this rating, Avis had 2 buy ratings, 3...
-
Stock market today: Dow slides as signs of sticky inflation push up Fed hike bets
By Yasin Ebrahim Investing.com -- The Dow closed lower Tuesday, as investors digested the latest data showing signs of cooling, but stickier inflation that triggered a jump in Treasury...
-
S&P 500 in choppy action as signs of sticky inflation push Treasury yields higher
By Yasin Ebrahim Investing.com -- The S&P 500 struggled for direction Tuesday, as stocks gyrated wildly on surging Treasury yields after the data showed that inflation is cooling, but some...
-
Midday movers: Boeing, Silvergate Capital, Palantir Technologies and more
By Liz Moyer Investing.com -- Stocks were mixed on Tuesday after a slightly hotter than expected consumer price index for the year ending in January. Here are the midday movers for Feb....
-
After-hours movers: Palantir, Avis gain following earnings
By Investing.com Staff Palantir (NYSE:PLTR) 16% HIGHER; {{erl-1166239||reported Q4 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $509...
-
Avis Budget revenue beat expectation on travel, commercial boost
By Liz Moyer Investing.com -- Avis Budget Group Inc (NASDAQ:CAR) beat expectations for fourth-quarter earnings, saying revenue rose 8% on strong holiday travel and its commercial...
-
Avis Budget Group Tops Q4 EPS by $3.65
Avis Budget Group (CAR) reported Q4 EPS of $10.46, $3.65 better than the analyst estimate of $6.81. Revenue for the quarter came in at $2.8 billion versus the consensus estimate of $2.69...
-
Avis earnings beat by $3.65, revenue topped estimates
Investing.com - Avis (NASDAQ: CAR) reported fourth quarter EPS of $10.46, $3.65 better than the analyst estimate of $6.81. Revenue for the quarter came in at $2.8B versus the consensus...
-
ZOOZ Power Signs MOU with Unnamed Rental Company to Build Ultra-Fast EV Chargers
By Michael Elkins ZOOZ Power (formerly Chakratec), a leading supplier of Flywheel-based Power Boosting solutions, has signed a binding memorandum of understanding with an unnamed global car...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
